Skip to main content
Journal cover image

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

Publication ,  Journal Article
Ng, K; Meyerhardt, JA; Chan, AT; Sato, K; Chan, JA; Niedzwiecki, D; Saltz, LB; Mayer, RJ; Benson, AB; Schaefer, PL; Whittom, R; Hantel, A ...
Published in: J Natl Cancer Inst
January 2015

We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

January 2015

Volume

107

Issue

1

Start / End Page

345

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sex Factors
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Odds Ratio
  • Neoplasm Staging
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Leucovorin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ng, K., Meyerhardt, J. A., Chan, A. T., Sato, K., Chan, J. A., Niedzwiecki, D., … Fuchs, C. S. (2015). Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst, 107(1), 345. https://doi.org/10.1093/jnci/dju345
Ng, Kimmie, Jeffrey A. Meyerhardt, Andrew T. Chan, Kaori Sato, Jennifer A. Chan, Donna Niedzwiecki, Leonard B. Saltz, et al. “Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.J Natl Cancer Inst 107, no. 1 (January 2015): 345. https://doi.org/10.1093/jnci/dju345.
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015 Jan;107(1):345.
Ng, Kimmie, et al. “Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.J Natl Cancer Inst, vol. 107, no. 1, Jan. 2015, p. 345. Pubmed, doi:10.1093/jnci/dju345.
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015 Jan;107(1):345.
Journal cover image

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

January 2015

Volume

107

Issue

1

Start / End Page

345

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sex Factors
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Odds Ratio
  • Neoplasm Staging
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Leucovorin